Clincosm LogoSign in Get a demo

Metastatic Pancreatic Ductal Adenocarcinoma

Showing 1 - 25 of 26
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With

Recruiting
  • Pancreatic Cancer
  • +4 more
  • PET Scan
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 10, 2023

Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Seattle (Autologous Mesothelin-specific

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Stage IV Pancreatic Cancer AJCC v8
  • Autologous Mesothelin-specific TCR-T Cells
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 31, 2023

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Worldwide (NIS793, Nab-paclitaxel, Gemcitabine)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Fayetteville, Arkansas
  • +122 more
Jan 27, 2023

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Washington (BXCL701, Pembrolizumab)

Not yet recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023

Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 Trial

Not yet recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • +3 more
  • Biopsy
  • +8 more
  • (no location specified)
Jan 13, 2023

Metastatic Pancreatic Ductal Adenocarcinoma Trial in United States (Botensilimab, Gemcitabine, Nab-paclitaxel)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Scottsdale, Arizona
  • +13 more
Jan 6, 2023

Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC

Recruiting
  • Locally Advanced Pancreatic Ductal Adenocarcinoma
  • +7 more
  • Gemcitabine Hydrochloride
  • +8 more
  • Philadelphia, Pennsylvania
  • +1 more
Dec 20, 2022

Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma Trial in New

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • +12 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 30, 2022

Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)

Recruiting
  • Pancreatic Adenocarcinoma Metastatic
  • +14 more
  • Boston, Massachusetts
  • +1 more
Dec 6, 2022

Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7 Trial in

Recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 26, 2022

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Belgium, France, Spain (CD40 agonist mitazalimab in combination with chemo)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • CD40 agonist mitazalimab in combination with chemotherapy
  • Brussels, Belgium
  • +15 more
Aug 12, 2022

Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma Trial in Washington (Eryaspase,

Active, not recruiting
  • Locally Advanced Pancreatic Ductal Adenocarcinoma
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Aug 3, 2022

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Belgium (Nanoliposomal irinotecan, 5 FU, Leucovorin)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Nanoliposomal irinotecan
  • +3 more
  • Brugge, West-Vlaanderen, Belgium
  • +11 more
Jul 25, 2022

Metastatic Pancreatic Ductal Adenocarcinoma Trial in United States (Ketogenic Diet)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Ketogenic Diet
  • Scottsdale, Arizona
  • +6 more
Jun 9, 2022

Metastatic Pancreatic Ductal Adenocarcinoma Trial in United States (Relacorilant, 100 mg and 25 mg, Nab paclitaxel)

Terminated
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Relacorilant, 100 mg and 25 mg
  • Nab paclitaxel
  • Scottsdale, Arizona
  • +17 more
May 11, 2022

Metastatic Pancreatic Ductal Adenocarcinoma Trial in France, Spain (CAN04, FOLFIRINOX)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Bordeaux, France
  • +7 more
May 16, 2022

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Boston, New York (Canakinumab injection; spartalizumab, nab-paclitaxel,

Active, not recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
  • Boston, Massachusetts
  • +1 more
Apr 5, 2022

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +11 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Mar 22, 2022

Tolerability of Liposomal Irinotecan

Active, not recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Onivyde® + 5-FULV
  • Edegem, Belgium
    Antwerp University Hosptital
Jan 31, 2022

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Friedrichshafen (OFF, FOLFIRI Protocol)

Terminated
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • OFF
  • FOLFIRI Protocol
  • Friedrichshafen, Germany
    Praxis für Innere Medizin
Dec 21, 2021

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Spain, United States (Palbociclib, Nab-Paclitaxel)

Completed
Has Results
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Scottsdale, Arizona
  • +25 more
Mar 10, 2021

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Singapore (Ciprofloxacin)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Singapore, Singapore
    National University Hospital
Aug 19, 2020

Metastatic Pancreatic Ductal Adenocarcinoma Trial in United Kingdom, United States (MEDI4736 in combination with nab-paclitaxel

Completed
Has Results
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • MEDI4736 in combination with nab-paclitaxel and gemcitabine
  • MEDI4736 in combination with AZD5069
  • Rochester, New York
  • +6 more
Jul 26, 2019

Metastatic Pancreatic Ductal Adenocarcinoma Trial in United States (Momelotinib, Placebo to match momelotinib, Nab-paclitaxel)

Terminated
Has Results
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Los Angeles, California
  • +3 more
Jan 31, 2019

Metastatic Pancreatic Ductal Adenocarcinoma Trial in United States (PF-04136309, Nab-paclitaxel, Gemcitabine)

Terminated
Has Results
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Boston, Massachusetts
  • +17 more
Feb 1, 2019